XTL Biopharmaceuticals Ltd. XTLB
NASDAQ
| 09/30/2025 | 12/31/2024 | 06/30/2024 | 12/31/2023 | ||
|---|---|---|---|---|---|
| Revenue | -- | 405.00K | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | 405.00K | -- | -- | |
| Cost of Revenue | -- | 448.00K | -- | -- | |
| Gross Profit | -- | -43.00K | -- | -- | |
| SG&A Expenses | -- | 737.00K | 415.00K | 194.00K | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | -- | 1.22M | 421.00K | 200.00K | |
| Operating Income | -- | -812.00K | -421.00K | -200.00K | |
| Income Before Tax | -- | -385.00K | -704.00K | -284.00K | |
| Income Tax Expenses | -- | -130.00K | -- | -- | |
| Earnings from Continuing Operations | -- | -255.00K | -704.00K | -284.00K | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -- | -255.00K | -704.00K | -284.00K | |
| EBIT | -- | -812.00K | -421.00K | -200.00K | |
| EBITDA | -- | -762.30K | -- | -199.80K | |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | |
| Normalized Basic EPS | -- | 0.00 | -- | 0.00 | |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | |
| Normalized Diluted EPS | -- | 0.00 | -- | 0.00 | |
| Average Basic Shares Outstanding | -- | 883.67M | 544.91M | 544.91M | |
| Average Diluted Shares Outstanding | 883.67M | 883.67M | 544.91M | 544.91M | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |